AQR Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-5,957
| Closed | -$607K | – | 2415 |
|
|
2023
Q2 | $607K | Sell |
5,957
-232
| -4% | -$22K | ﹤0.01% | 1729 |
|
|
2023
Q1 | $554K | Buy |
+6,189
| New | +$363K | ﹤0.01% | 1744 |
|
|
2022
Q2 | – | Sell |
-8,677
| Closed | -$284K | – | 2332 |
|
|
2022
Q1 | $284K | Buy |
+8,677
| New | +$257K | ﹤0.01% | 1976 |
|
|
2021
Q1 | – | Sell |
-3,204
| Closed | -$393K | – | 2293 |
|
|
2020
Q4 | $393K | Sell |
3,204
-713
| -18% | -$93.7K | ﹤0.01% | 1870 |
|
|
2020
Q3 | $378K | Sell |
3,917
-11,475
| -75% | -$1.43M | ﹤0.01% | 1842 |
|
|
2020
Q2 | $2.4M | Sell |
15,392
-305
| -2% | -$46.4K | ﹤0.01% | 1077 |
|
|
2020
Q1 | $2.27M | Buy |
15,697
+5,620
| +56% | +$1.09M | ﹤0.01% | 1035 |
|
|
2019
Q4 | $2.06M | Sell |
10,077
-931
| -8% | -$170K | ﹤0.01% | 1262 |
|
|
2019
Q3 | $884K | Sell |
11,008
-339
| -3% | -$28.8K | ﹤0.01% | 1566 |
|
|
2019
Q2 | $1.07M | Sell |
11,347
-7,288
| -39% | -$629K | ﹤0.01% | 1472 |
|
|
2019
Q1 | $1.59M | Sell |
18,635
-338
| -2% | -$28.1K | ﹤0.01% | 1405 |
|
|
2018
Q4 | $1.06M | Buy |
18,973
+14,311
| +307% | +$874K | ﹤0.01% | 1488 |
|
|
2018
Q3 | $381K | Sell |
4,662
-2,867
| -38% | -$202K | ﹤0.01% | 2039 |
|
|
2018
Q2 | $263K | Sell |
7,529
-3,521
| -32% | -$107K | ﹤0.01% | 2160 |
|
|
2018
Q1 | $227K | Hold |
11,050
| – | – | ﹤0.01% | 2111 |
|
|
2017
Q4 | $313K | Sell |
11,050
-2,387
| -18% | -$66.6K | ﹤0.01% | 2057 |
|
|
2017
Q3 | $418K | Buy |
+13,437
| New | +$404K | ﹤0.01% | 1998 |
|
Other funds holding RETA
AQR Capital Management's RETA Position: Q3 2023 in Review
AQR Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 5,957 shares — an estimated $607K sold.
AQR Capital Management first reported a position in RETA in Q3 2017 and held it in 17 quarters. The position peaked at $2.4M in Q2 2020. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- AQR Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- AQR Capital Management sold 5,957 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $607K.
- AQR Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 17 quarters.
- AQR Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.4M in Q2 2020.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on AQR Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.